Castle Biosciences, Inc. (CSTL)

From the record

Castle Biosciences, Inc.'s filings since 2017 show 1 warning event: a debt default or acceleration notice (8-K item 2.04, the latest 2020-03-05) (its current reports).

From the record

Castle Biosciences, Inc.'s 8 filed years say what it did: revenue went from $23 million in fiscal 2018 to $344 million in fiscal 2025, up 47.4% a year; it rose in 7 of 7 years; it never fell from a peak; net income was positive in 2 of 8 of those years (its annual reports).

From the record

Over the 3 fiscal years to 2025-12-31, Castle Biosciences, Inc.'s diluted share count grew about 3.6% a year, and dividends and buybacks returned about 0% of its operating cash flow over 3 years (its filed statements). Its officers and directors filed 219 sales (210 under scheduled 10b5-1 plans) and 0 purchases of their own stock on the open market in the year to 2026-11-12 (their Form 4 filings).

From the record

Return on equity: in the fiscal year ended 2025-12-31, Castle Biosciences, Inc. lost about 5 cents for every dollar of shareholders' money, and gross profitability: its products earned about 47 cents per dollar of everything the company owns (revenue less the cost of revenue). Leverage: it owed about 19 cents per dollar of assets, and net share issuance: its share count shrank 0.9% over the year (the filed statements).

From the record

Castle Biosciences, Inc.'s standing among 24 graded names in its industry family: revenue of $344 million in fiscal 2025 ranks in the top 37% by size; a net margin of -7% ranks in the top 35%; revenue growth of 35.9% a year over the last 3 filed years ranks in the top 24% (its annual reports).

From the record

Castle Biosciences, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Maetzold, Derek J (Pres. & Chief Exec. Officer, as filed), filing under that title since 2019-07-24, 7.3 years (top 21% of its family); the 11 officers and directors filing in the last fifteen months have been on the record a median of 5.6 years (top 50%); 1 officer or director change was reported on Form 8-K since 2023-11-13, against the 11 people in charge now (top 11%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

From the record

Castle Biosciences, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $117 million against debt of $10 million leaves 18.5% of its assets as net cash, top 40% of its family; cash from operations less capital spending is 8.2% of revenue (top 27%); a gross margin of 79.4% (top 3%); research spending of 15.1% of revenue (bottom 36%) (its annual report).

From the record

Castle Biosciences, Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew 35.9% a year over the last three filed years against 47.4% over all 8, slowing (bottom 37% of its family); the newest year grew 3.7% (bottom 24%); research spending grew 4.9% a year (top 36%); capital spending grew 85.6% a year (top 12%) (its annual reports). Castle Biosciences, Inc. reported 2 product lines in fiscal 2025: Dermatologic at $216 million (63%), Non Dermatologic at $128 million (37%); 1 of 2 grew against the year before (its annual report).

From the record

Castle Biosciences, Inc.'s newest year against its own record: revenue of $344 million in fiscal 2025 came in 33.4% below the $517 million its prior three years' pace pointed to (bottom 8% of its family); net income of $24 million against a prior three-year average of $35 million (top 32%); a net margin of -7% against -23.2% before (bottom 38%) (its annual reports).